Soligenix Inc  

(Public, OTCBB:SNGX)   Watch this stock  
Find more results for OTC:SNGX
2.00
+0.01 (0.50%)
Aug 28 - Close
OTCBB data delayed by 15 mins - Disclaimer
Currency in USD
Range 1.97 - 2.07
52 week 1.65 - 2.50
Open 1.99
Vol / Avg. 26,763.00/25,204.00
Mkt cap 40.16M
P/E     -
Div/yield     -
EPS -0.51
Shares 20.08M
Beta 2.26
Inst. own 22%
Sep 22, 2014
Soligenix Inc at Maxim Group's Institutional NYC BioDefense Mini-Conference Add to calendar
Sep 9, 2014
Soligenix Inc at Rodman & Renshaw Global Investment Conference - 1:15PM EDT - Add to calendar
Aug 11, 2014
Q2 2014 Soligenix Inc Earnings Release
  

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin -66.88% -311.99%
Operating margin -119.57% -221.97%
EBITD margin - -214.83%
Return on average assets -57.82% -155.11%
Return on average equity - -1129.41%
Employees 17 -
CDP Score - -

Address

Suite C-10, 29 Emmons Drive
PRINCETON, NJ 8540
United States - Map
+1-609-5388200 (Phone)
+1-609-4526467 (Fax)

Website links

Description

Soligenix, Inc. is a development-stage biopharmaceutical company. The Company is focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need. The Company operates in two segments: BioTherapeutics and Vaccines/BioDefense. Its BioTherapeutics business segment intends to develop oral beclomethasone dipropionate (oral BDP) indications such as pediatric Crohn�s disease and acute radiation enteritis. Its Vaccines/BioDefense business segment includes active development programs for RiVaxTM, its ricin toxin vaccine, and VeloThrax, its anthrax vaccine, and OrbeShield, its gastrointestinal acute radiation syndrome (GI ARS) therapeutic. In December 2012, it acquired a drug technology, it refers to as SGX94, representing an approach to modulation of the innate immune system. SGX94 is an IDR that regulates the innate immune system to simultaneously reduce inflammation, eliminate infection and enhance tissue healing.

Officers and directors

Christopher J. Schaber Ph.D. Chairman of the Board, President, Chief Executive Officer
Age: 47
Joseph M. Warusz CPA Acting Chief Financial Officer, Vice President - Finance, Corporate Secretary
Age: 57
Robert N. Brey Ph.D. Senior Vice President, Chief Scientific Officer
Age: 63
Richard Straube M.D. Senior Vice President and Chief Medical Officer
Age: 62
Marco Maria Brughera Director
Age: 58
Keith L. Brownlie CPA Independent Director
Age: 61
Gregg Anthony Lapointe CPA Independent Director
Age: 55
Robert Joseph Rubin M.D. Independent Director
Age: 68
Jerome B. Zeldis M.D., Ph.D. Independent Director
Age: 64